Name (Synonyms) | Correlation | |
---|---|---|
drug4 | 0.12% Chlorhexidine oral/nasal rinse Wiki | 0.41 |
drug2181 | Saline oral/nasal rinse Wiki | 0.41 |
drug89 | ATV Wiki | 0.41 |
drug1430 | Mannitol Wiki | 0.41 |
drug307 | BR Wiki | 0.41 |
drug503 | CUVITRU Wiki | 0.41 |
drug705 | DRV Wiki | 0.41 |
drug6 | 0.5% Povidone/Iodine oral/nasal rinse Wiki | 0.41 |
drug594 | Cobicistat Wiki | 0.41 |
drug647 | Convalescent Plasma Wiki | 0.09 |
drug1978 | Questionnaire Wiki | 0.09 |
drug1086 | Hydroxychloroquine Wiki | 0.04 |
Name (Synonyms) | Correlation | |
---|---|---|
D000163 | Acquired Immunodeficiency Syndrome NIH | 0.24 |
D015658 | HIV Infections NIH | 0.17 |
D000077062 | Burnout, Psychological NIH | 0.12 |
D004194 | Disease NIH | 0.07 |
D003141 | Communicable Diseases NIH | 0.04 |
D007239 | Infection NIH | 0.02 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.02 |
D018352 | Coronavirus Infections NIH | 0.02 |
There are 6 clinical trials
Cohort 1: The primary objectives are: - To evaluate the steady-state pharmacokinetics (PK) of Atazanavir (ATV) and Darunavir (DRV) and confirm the dose of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) in HIV-1 infected, virologically suppressed adolescent participants weighing ≥ 25 kg (12 to < 18 years of age) - To evaluate the safety and tolerability of ATV/co or DRV/co through 24 weeks in HIV-1 infected, virologically suppressed adolescent participants weighing ≥ 25 kg (12 to < 18 years of age) Cohort 2: The primary objectives are: - To evaluate the steady-state PK of ATV and DRV and confirm the dose of ATV/co or DRV/co in HIV-1 infected, virologically suppressed pediatric participants weighing ≥ 25 to < 35 kg (6 to < 12 years of age) - To evaluate the steady-state PK of tenofovir alafenamide (TAF) and confirm the dose of emtricitabine/tenofovir alafenamide (F/TAF) in HIV-1 infected, virologically suppressed pediatric participants weighing ≥ 25 to < 35 kg (6 to < 12 years of age) - To evaluate the safety and tolerability of ATV/co, DRV/co, and F/TAF through 24 weeks in HIV-1 infected, virologically suppressed pediatric participants weighing ≥ 25 to < 35 kg (6 to < 12 years of age) Cohort 3: The primary objectives are: - To evaluate the steady-state PK of ATV and DRV and confirm the dose of ATV/co or DRV/co in HIV-1 infected, virologically suppressed pediatric participants weighing ≥ 14 to < 25 kg (≥ 3 years of age) - To evaluate the steady-state PK of TAF and confirm the dose of F/TAF in HIV-1 infected, virologically suppressed pediatric participants weighing ≥ 14 to < 25 kg (≥ 3 years of age) - To evaluate the safety and tolerability of ATV/co, DRV/co, and F/TAF through 24 weeks in HIV-1 infected, virologically suppressed pediatric participants weighing ≥ 14 to < 25 kg (≥ 3 years of age)
Description: AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).
Measure: Pharmacokinetic (PK) Parameter: AUCtau of ATV and DRV Time: Predose, 1, 2, 3, 4, 5, 8, and 12 hours postdose on Day 10Description: AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).
Measure: Pharmacokinetic (PK) Parameter: AUCtau of ATV, DRV, and TAF for Cohorts 2 and 3 Time: Predose 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose at Week 2 or Week 4Description: Ctau is defined as the observed drug concentration at the end of the dosing interval.
Measure: PK Parameter: Ctau of ATV, DRV, and COBI for Cohort 1 Time: Intensive PK samples at Predose, 1, 2, 3, 4, 5, 8, and 12 hours postdose on Day 10. Trough PK samples at Day 1 prior to adminstering COBI and at Weeks 12, 24, and 48 (Part A), or at Weeks 4, 12, 24, 32, and 48 (Part B).Description: Cmax is defined as the maximum observed concentration of drug.
Measure: PK Parameter: Cmax of ATV, DRV, and COBI for Cohort 1 Time: Intensive PK samples at Predose, 1, 2, 3, 4, 5, 8, and 12 hours postdose on Day 10. Trough PK samples at Day 1 prior to adminstering COBI and at Weeks 12, 24, and 48 (Part A), or at Weeks 4, 12, 24, 32, and 48 (Part B).Description: CL/F is defined as the apparent oral clearance following administration of the drug.
Measure: PK Parameter: CL/F of ATV, DRV, and COBI for Cohort 1 Time: Intensive PK samples at Predose, 1, 2, 3, 4, 5, 8, and 12 hours postdose on Day 10. Trough PK samples at Day 1 prior to adminstering COBI and at Weeks 12, 24, and 48 (Part A), or at Weeks 4, 12, 24, 32, and 48 (Part B).Description: Vz/F is defined as the apparent volume of distribution of the drug.
Measure: PK Parameter: Vz/F of COBI for Cohort 1 Time: Intensive PK samples at Predose, 1, 2, 3, 4, 5, 8, and 12 hours postdose on Day 10. Trough PK samples at Day 1 prior to adminstering COBI and at Weeks 12, 24, and 48 (Part A), or at Weeks 4, 12, 24, 32, and 48 (Part B).Description: Ctau is defined as the observed drug concentration at the end of the dosing interval.
Measure: PK Parameter: Ctau of ATV, DRV, COBI, FTC, and TFV for Cohorts 2 and 3 Time: Intensive PK samples at Predose 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose at Week 2 or Week 4. Trough PK samples at Weeks 8, 24, and 36, and timed PK samples (15 minutes to 3 hours post-dose) at Weeks 12, 16, and 48Description: Cmax is defined as the maximum observed concentration of drug.
Measure: PK Parameter: Cmax of ATV, DRV, COBI, TAF, FTC and TFV for Cohorts 2 and 3 Time: Intensive PK samples at Predose 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose at Week 2 or Week 4. Trough PK samples at Weeks 8, 24, and 36, and timed PK samples (15 minutes to 3 hours post-dose) at Weeks 12, 16, and 48Description: CL/F is defined as the apparent oral clearance following administration of the drug.
Measure: PK Parameter: CL/F of ATV, DRV, and TAF for Cohorts 2 and 3 Time: Intensive PK samples at Predose 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose at Week 2 or Week 4. Trough PK samples at Weeks 8, 24, and 36, and timed PK samples (15 minutes to 3 hours post-dose) at Weeks 12, 16, and 48Description: Vz/F is defined as the apparent volume of distribution of the drug.
Measure: PK Parameter: Vz/F of COBI and TAF for Cohorts 2 and 3 Time: Intensive PK samples at Predose 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose at Week 2 or Week 4. Trough PK samples at Weeks 8, 24, and 36, and timed PK samples (15 minutes to 3 hours post-dose) at Weeks 12, 16, and 48This study will provide insights on the infusion parameters, dosing, and experience of participants transitioning to CUVITRU in a real-world setting.
Description: Median infusion volume per site
Measure: Infusion parameter 1: Cohort 1-Start of data collection Time: BaselineDescription: Median infusion volume per site
Measure: Infusion parameter 1: Cohort 1- Month 3 Time: Month 3Description: Median infusion volume per site
Measure: Infusion parameter 1: Cohort 1- Month 6 Time: Month 6Description: Median infusion volume per site
Measure: Infusion parameter 1: Cohort 1- 12 Month final follow-up Time: 12 Month final follow-upDescription: Median infusion volume per site
Measure: Infusion parameter 1: Cohort 2- Start of data collection Time: BaselineDescription: Median infusion volume per site
Measure: Infusion parameter 1: Cohort 2- 12 Month final follow-up Time: 12 Month final follow-upDescription: Median infusion volume per infusion
Measure: Infusion parameter 1.1: Cohort 1- Start of data collection Time: BaselineDescription: Median infusion volume per infusion
Measure: Infusion parameter 1.1: Cohort 1- Month 3 Time: Month 3Description: Median infusion volume per infusion
Measure: Infusion parameter 1.1: Cohort 1- Month 6 Time: Month 6Description: Median infusion volume per infusion
Measure: Infusion parameter 1.1: Cohort 1- 12 Month final follow-up Time: 12 Month final follow-upDescription: Median infusion volume per infusion
Measure: Infusion parameter 1.1: Cohort 2- Start of data collection Time: BaselineDescription: Median infusion volume per infusion
Measure: Infusion parameter 1.1: Cohort 2- 12 Month final follow-up Time: 12 Month final follow-upDescription: Median number of infusion sites
Measure: Infusion parameter 2: Cohort 1- Start of data collection Time: BaselineDescription: Median number of infusion sites
Measure: Infusion parameter 2: Cohort 1- Month 3 Time: Month 3Description: Median number of infusion sites
Measure: Infusion parameter 2: Cohort 1- Month 6 Time: Month 6Description: Median number of infusion sites
Measure: Infusion parameter 2: Cohort 1- 12 Month final follow-up Time: 12 Month final follow-upDescription: Median number of infusion sites
Measure: Infusion parameter 2: Cohort 2- Start of data collection Time: BaselineDescription: Median number of infusion sites
Measure: Infusion parameter 2: Cohort 2- 12 Month final follow-up Time: 12 Month final follow-upDescription: Median infusion duration
Measure: Infusion parameter 3: Cohort 1- Start of data collection Time: BaselineDescription: Median infusion duration
Measure: Infusion parameter 3: Cohort 1- Month 3 Time: Month 3Description: Median infusion duration
Measure: Infusion parameter 3: Cohort 1- Month 6 Time: Month 6Description: Median infusion duration
Measure: Infusion parameter 3: Cohort 1- 12 Month final follow-up Time: 12 Month final follow-upDescription: Median infusion duration
Measure: Infusion parameter 3: Cohort 2- Start of data collection Time: BaselineDescription: Median infusion duration
Measure: Infusion parameter 3: Cohort 2- 12 Month final follow-up Time: 12 Month final follow-upDescription: Median number of infusions to reach participant's maximum infusion volume
Measure: Infusion parameter 3.1: Cohort 1- Month 3 Follow-up Time: Month 3Description: Median number of infusions to reach participant's maximum infusion volume
Measure: Infusion parameter 3.1: Cohort 1- Month 6 Follow-up Time: Month 6Description: Median number of infusions to reach participant's maximum infusion volume
Measure: Infusion parameter 3.1: Cohort 1- 12 Month final follow-up Time: 12 Month final follow-upDescription: Median number of infusions to reach participant's maximum infusion volume
Measure: Infusion parameter 3.1: Cohort 2- 12 Month final follow-up Time: 12 Month final follow-upDescription: Median number of infusions per month per participant
Measure: Infusion parameter 3.2: Cohort 1- Start of data collection Time: BaselineDescription: Median number of infusions per month per participant
Measure: Infusion parameter 3.2: Cohort 1- Month 3 Time: Month 3Description: Median number of infusions per month per participant
Measure: Infusion parameter 3.2: Cohort 1- Month 6 Time: Month 6Description: Median number of infusions per month per participant
Measure: Infusion parameter 3.2: Cohort 1- 12 Month final follow-up Time: 12 Month final follow-upDescription: Median number of infusions per month per participant
Measure: Infusion parameter 3.2: Cohort 2- Start of data collection Time: BaselineDescription: Median number of infusions per month per participant
Measure: Infusion parameter 3.2: Cohort 2- 12 Month final follow-up Time: 12 Month final follow-upDescription: Median number of infusions to reach final dose interval per participant
Measure: Infusion parameter 3.3: Cohort 1- Start of data collection Time: BaselineDescription: Median number of infusions to reach final dose interval per participant
Measure: Infusion parameter 3.3: Cohort 1- Month 3 Time: Month 3Description: Median number of infusions to reach final dose interval per participant
Measure: Infusion parameter 3.3: Cohort 1- Month 6 Time: Month 6Description: Median number of infusions to reach final dose interval per participant
Measure: Infusion parameter 3.3: Cohort 1- 12 Month final follow-up Time: 12 Month final follow-upDescription: Median number of infusions to reach final dose interval per participant
Measure: Infusion parameter 3.3: Cohort 2- Start of data collection Time: BaselineDescription: Median number of infusions to reach final dose interval per participant
Measure: Infusion parameter 3.3: Cohort 2- 12 Month final follow-up Time: 12 Month final follow-upDescription: Median maximal infusion rate per site
Measure: Infusion parameter 4.1: Cohort 1- Start of data collection Time: BaselineDescription: Median maximal infusion rate per site
Measure: Infusion parameter 4.1: Cohort 1- Month 3 Time: Month 3Description: Median maximal infusion rate per site
Measure: Infusion parameter 4.1: Cohort 1- Month 6 Time: Month 6Description: Median maximal infusion rate per site
Measure: Infusion parameter 4.1: Cohort 1- 12 Month final follow-up Time: 12 Month final follow-upDescription: Median maximal infusion rate per site
Measure: Infusion parameter 4.1: Cohort 2- Start of data collection Time: BaselineDescription: Median maximal infusion rate per site
Measure: Infusion parameter 4.1: Cohort 2- 12 Month final follow-up Time: 12 Month final follow-upDescription: Number of infusions that are discontinued, slowed, or interrupted
Measure: Infusion parameter 4.2: Cohort 1- Start of data collection Time: BaselineDescription: Number of infusions that are discontinued, slowed, or interrupted
Measure: Infusion parameter 4.2: Cohort 1- Month 3 Time: Month 3Description: Number of infusions that are discontinued, slowed, or interrupted
Measure: Infusion parameter 4.2: Cohort 1- Month 6 Time: Month 6Description: Number of infusions that are discontinued, slowed, or interrupted
Measure: Infusion parameter 4.2: Cohort 1- 12 Month final follow-up Time: 12 Month final follow-upDescription: Number of infusions that are discontinued, slowed, or interrupted
Measure: Infusion parameter 4.2: Cohort 2- Start of data collection Time: BaselineDescription: Number of infusions that are discontinued, slowed, or interrupted
Measure: Infusion parameter 4.2: Cohort 2- 12 Month final follow-up Time: 12 Month final follow-upDescription: Median number of infusions to reach participant's maximum infusion rate
Measure: Infusion parameter 4.3: Cohort 1- Month 3 Time: Month 3Description: Median number of infusions to reach participant's maximum infusion rate
Measure: Infusion parameter 4.3: Cohort 1- Month 6 Time: Month 6Description: Median number of infusions to reach participant's maximum infusion rate
Measure: Infusion parameter 4.3: Cohort 1- 12 Month final follow-up Time: 12 Month final follow-upDescription: Median number of infusions to reach participant's maximum infusion rate
Measure: Infusion parameter 4.3: Cohort 2- 12 Month final follow-up Time: 12 Month final follow-upDescription: Mean dose
Measure: Infusion parameter 5.1: Cohort 1- Start of data collection Time: BaselineDescription: Mean dose
Measure: Infusion parameter 5.1: Cohort 1- Month 3 Time: Month 3Description: Mean dose
Measure: Infusion parameter 5.1: Cohort 1- Month 6 Time: Month 6Description: Mean dose
Measure: Infusion parameter 5.1: Cohort 1- 12 Month final follow-up Time: 12 Month final follow-upDescription: Mean dose
Measure: Infusion parameter 5.1: Cohort 2- Start of data collection Time: BaselineDescription: Mean dose
Measure: Infusion parameter 5.1: Cohort 2- 12 Month final follow-up Time: 12 Month final follow-upDescription: Mean dosing interval
Measure: Infusion parameter 5.2: Cohort 1- Start of data collection Time: BaselineDescription: Mean dosing interval
Measure: Infusion parameter 5.2: Cohort 1- Month 3 Time: Month 3Description: Mean dosing interval
Measure: Infusion parameter 5.2: Cohort 1- Month 6 Time: Month 6Description: Mean dosing interval
Measure: Infusion parameter 5.2: Cohort 1- 12 Month final follow-up Time: 12 Month final follow-upDescription: Mean dosing interval
Measure: Infusion parameter 5.2: Cohort 2- Start of data collection Time: BaselineDescription: Mean dosing interval
Measure: Infusion parameter 5.2: Cohort 2- 12 Month final follow-up Time: 12 Month final follow-upDescription: Mean number of dose adjustments
Measure: Infusion parameter 5.3: Cohort 1- Start of data collection Time: BaselineDescription: Mean number of dose adjustments
Measure: Infusion parameter 5.3: Cohort 1- Month 3 Time: Month 3Description: Mean number of dose adjustments
Measure: Infusion parameter 5.3: Cohort 1- Month 6 Time: Month 6Description: Mean number of dose adjustments
Measure: Infusion parameter 5.3: Cohort 1- 12 Month final follow-up Time: 12 Month final follow-upDescription: Mean number of dose adjustments
Measure: Infusion parameter 5.3: Cohort 2- Start of data collection Time: BaselineDescription: Mean number of dose adjustments
Measure: Infusion parameter 5.3: Cohort 2- 12 Month final follow-up Time: 12 Month final follow-upDescription: TSQM-9 is a 9-item, validated, self-administered instrument used to assess participant's satisfaction with medication. The three domains assessed are effectiveness, convenience, and global satisfaction
Measure: Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9): Cohort 1 Time: 12 Month final follow-upDescription: TSQM-9 is a 9-item, validated, self-administered instrument used to assess participant's satisfaction with medication. The three domains assessed are effectiveness, convenience, and global satisfaction
Measure: Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9): Cohort 2 Time: 12 Month final follow-upDescription: The LQI is a self-administered questionnaire developed specifically for participants/legal guardians involved in IVIG treatments. It consists of 15-items, divided into four domains: treatment interferences (6 items), therapy-related problems (4 items), therapy setting (3 items), and treatment costs (2 items). Items are rated on a 7-point Likert-type scale ranging from 1: "Extremely bad" to 7: "Extremely good". Total scores range from 15 to 105, with higher scores indicating the highest possible satisfaction with factors such as independence, therapy convenience, social/school/work activities, and health and travel costs
Measure: Life Quality Index (LSI): Cohort 1 Time: 12 Month final follow-upDescription: The LQI is a self-administered questionnaire developed specifically for participants/legal guardians involved in IVIG treatments. It consists of 15-items, divided into four domains: treatment interferences (6 items), therapy-related problems (4 items), therapy setting (3 items), and treatment costs (2 items). Items are rated on a 7-point Likert-type scale ranging from 1: "Extremely bad" to 7: "Extremely good". Total scores range from 15 to 105, with higher scores indicating the highest possible satisfaction with factors such as independence, therapy convenience, social/school/work activities, and health and travel costs
Measure: Life Quality Index (LSI): Cohort 2 Time: 12 Month final follow-upDescription: The TPQ is a self-administered questionnaire developed to assess participants' preference towards the administration of new subcutaneous immunoglobulin G (SCIG) therapy. There are 4-items on the questionnaire, which investigate a participant's preference on the clinic/hospital/home setting of receiving the immunoglobulin therapy, the participant's rating on the frequency and method of administration, and the participant's preference to continue receiving the SCIG treatment.
Measure: Treatment Preference Questionnaire: Cohort 1 Time: 12 Month final follow-upDescription: The TPQ is a self-administered questionnaire developed to assess participants' preference towards the administration of new subcutaneous immunoglobulin G (SCIG) therapy. There are 4-items on the questionnaire, which investigate a participant's preference on the clinic/hospital/home setting of receiving the immunoglobulin therapy, the participant's rating on the frequency and method of administration, and the participant's preference to continue receiving the SCIG treatment.
Measure: Treatment Preference Questionnaire: Cohort 2 Time: 12 Month final follow-upCORIA is an observational cohort study of immunosuppressed populations who test positive for COVID-19. This includes people living with HIV, cancer, acquired immunodeficiency associated with other immunosuppressive therapy, primary immunodeficiency and recipients of a solid organ transplant. Participants will have routine clinical data collected with optional baseline collection and storage of a blood sample for storage . The study will be conducted in up to 30 sites within Australia.
A weekly questionnaire is sent to patients and parents of patients who are vulnerable for infections. Possible symptoms of COVID19 are asked for and use of healthcare services and testing for COVID19. Weekly reports are being send to the national institutions to update advice given to this group.
Description: To describe frequency of cough, fever, diarrhoea, shortness of breath, sore throat, blocked nose, red eyes, headache, joint pain, muscle pain, fatigue, chills, nausea, vomiting, diarrhoea over a year
Measure: To describe COVID19 infection in children/adults who are vulnerable for infection in an outpatients setting Time: 1 yearDescription: Patient/parent reported positive tests for COVID19
Measure: Number of children/adults tested positive for COVID19 Time: 1 yearDescription: Patient/parent reported admissions in hospital because of COVID19
Measure: Number of children/adults admitted in hospital because of COVID19 Time: 1 yearDescription: Patient/parent reported effect of COVID19 on daily activities
Measure: To assess the impact of COVID19 infection on the daily activities of immunosuppressed adults and children Time: 1 yearThe main objective of our project is to investigate the evolution of psychosocial, cardiovascular and immune markers in healthcare with different levels of exposure to the COVID-19 pandemic.
Description: Burnout - through self-reported stress and burnout thoughts, beliefs, emotions, behavior related to Covid-19 using Maslach Burnout Inventory. Maslach Burnout Inventory - is a 22-item survey that covers 3 areas: Emotional Exhaustion (EE), Depersonalization (DP), and low sense of Personal Accomplishment (PA). Each subscale includes multiple questions with frequency rating choices of Never, A few times a year or less, Once a month or less, A few times a month, Once a week, A few times a week, or Every day.
Measure: Change from Baseline Burnout at 2-3 months and 6 months Time: baseline, 2-3 months, 6 monthsDescription: Data is collected through wearable monitoring technology. Cardiovascular risk through monitoring of heart rate variability (HRV) markers. Changes of heart rate variability (HRV) reflecting cardiac autonomic dysfunction are associated with greater risks for cardiac morbidity and mortality.
Measure: Change from Baseline Cardiovascular Risk Cardiovascular Risk Through Heart Rate Variability Markers at 2-3 months and 6 months Time: baseline, 2-3 months, 6 monthsDescription: Data is collected through wearable monitoring technology. Actigraphy data is collected in 1 min epochs using the zero-crossing modes.
Measure: Change from Baseline Through Actigraphy at 2-3 months and 6 months Time: baseline, 2-3 months, 6 monthsDescription: Data is collected through wearable monitoring technology. Sleep efficiency is defined as the proportion of the estimated sleep periods spent asleep. Sleep latency is the length of time taken to fall asleep, calculated as the time between 'lights off' to the first period of 3 min of consecutive epochs scored as sleep.
Measure: Change from Baseline Through Sleep Quality at 2-3 months and 6 months Time: baseline, 2-3 months, 6 monthsDescription: Cardiovascular risk through Fuster-BEWAT score. The Fuster-BEWAT score will be analyzed as a continuous variable with total score ranging from 0 to 15 points. Additionally, each component will be categorized as ideal (3) or nonideal (0 to 2), and participants will be classified as having poor, intermediate, or ideal cardiovascular health based on the total number of ideal components (0 to 1 = poor, 2 to 3 = intermediate, 4 to 5 = ideal) (Fernández-Alvira et al., 2017).
Measure: Change from Baseline Cardiovascular Risk Through Fuster-BEWAT score at 2-3 months and 6 months Time: baseline, 2-3 months, 6 monthsDescription: Classification of the immune function will be screened.
Measure: Change from Baseline Immune Dysfunction at 2-3 months and 6 months Time: baseline, 2-3 months, 6 monthsDescription: Submaximal field test and maximal oxygen consumption (VO2, mL/kg/min).
Measure: Change from Baseline Cardio-Respiratory Fitness at 2-3 months and 6 months Time: baseline, 2-3 months, 6 monthsWith the emergence of SARS-CoV-2 and the COVID-19 pandemic, there is an urgent need to understand the impact of infection on immunodeficient individuals. Whilst co-morbidities (such as diabetes, cancer, arterial hypertension, heart disease...) have been documented in people infected with SARS-CoV-2, there is currently no information on the consequences and outcomes for individuals with primary immunodeficiencies (PID). Following the 1st phase of the survey (launched by Isabelle Meyts (ESID), Nizar Mahlaoui (CEREDIH & IPOPI) and Kate Sullivan with Stuart Tangye (IUIS), that gave an idea of the number of affected PID patients and the impact of SARS-CoV-2 and directly focusing on obtaining this top level of information), we are launching the 2nd phase: "COPID19". COPID19 survey is a secured online GDPR compliant platform based in Paris (Imagine Institute). It has been approved by the Paris-Necker-Enfants malades IRB and Ethics Committee. However, this retrospective survey is designed for global distribution. Data can be entered by a health care professional (mostly clinicians) through a personal login and password. Each documenting person will have access to his/her own patients' data. COPID19 require a greater level of information than the 1st phase. The eCRF will be open to evolutions depending on progresses in our knowledge of this pandemic.